BridgeBio have demonstrably boosted its course of a new treatment for cardiac amyloidosis, leveraging the investigational drug. Early clinical results reveals significant improvements for individuals affected by a serious condition. This focus underscores the company’s commitment to treating critical healthcare demands in this heart space. Attru